Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and Harvard universities, as well as helping coordinate the WHO’s…
Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest initial investment in Sanofi’s COVID-19 vaccine…
During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger Connor shared some of his insights regarding the reorganization of GSK’s Consumer Health, Pharmaceuticals and…
Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global Pharmaceutical and Biotechnology Conference last…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability. The life sciences industry within the United States makes significant contributions to…
During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact…
PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their strategies for success in one of the world’s most innovative nations.…
The latest from Southeast Asian pharma, including soaring output in Singapore, tax breaks for research in Indonesia, Thai firm Factorytalk’s UK expansion, and the potential for a Russian COVID-19 vaccine…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park highlights key takeaways from the BIOJapan 2020 conference on why San Diego offers a good example of what it takes…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
RemeGen, a low-profile Chinese biotech company based in Yantai city in the coastal Shandong province, around nine hours by train from the bustling biopharma hub of Shanghai, just made history…
See our Cookie Privacy Policy Here